Article in Cornea, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
5 authors.
Lindsey B De LottDepartment of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI.ORCID 0000-0003-2403-0207
Noreen KhanDepartment of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI.
Maria A WoodwardDepartment of Ophthalmology and Visual Sciences, University of Michigan Medical School, Ann Arbor, MI.
Daniel J ClauwDepartment of Anesthesiology, Chronic Pain and Fatigue Research Center University of Michigan Medical School, Ann Arbor, MI; and.
Anat GalorSurgical Services, Miami Veterans Administration Medical Center, Bascom Palmer Eye Institute, University of Miami, Miami, FL.
Funding
VIVARIUM MODULEP30EY007003 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI David Antonetti · 1987 to 2026
$17.6M
Shared Equipment ModuleP30EY014801 · NEI · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Victor L Perez · 2004 to 2026
$12.2M
University of Michigan BACPAC Mechanistic Research CenterU19AR076734 · NIAMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CLAUW, DANIEL J, HASSETT, AFTON L · 2019 to 2023
$12.2M
Transition from Acute to Chronic Pain After Thoracic SurgeryUM1NS118922 · NINDS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI BRUMMETT, CHAD M, CHANG, ANDREW CHING-HUNG · 2020 to 2022
$11.0M
Differentiation of Clinical Phenotypes of Inflammatory and Neuropathic Ocular Pain Conditions with Morphologic Measures and Functional Brain ImagingU01EY034686 · NEI · BOSTON CHILDREN'S HOSPITAL · PI Eric Alan Moulton · 2022 to 2026
$4.7M
Defining bacterial members of the ocular surface microbiome and assessing stability over timeU24EY035102 · NEI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI GALOR, ANAT, ST LEGER, ANTHONY J · 2023 to 2025
$3.3M
Peripheral and Central Nervous System Correlates of Persistent Post-Hysterectomy PainR01HD088712 · NICHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI AS-SANIE, SAWSAN, CLAUW, DANIEL J · 2017 to 2021
$3.0M
Tear protein biomarkers of refractive surgery painR33EY032468 · NEI · OREGON HEALTH & SCIENCE UNIVERSITY · PI AICHER, SUE A, GALOR, ANAT · 2023 to 2025
$2.9M
Quantifying Microbial Keratitis to Predict Outcomes: An Imaging and Epidemiologic ApproachR01EY031033 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI WOODWARD, MARIA ANNEKE · 2020 to 2023
$1.8M
Optimizing Treatment Decisions for Acute Demyelinating Optic NeuritisK23EY027849 · NEI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DE LOTT, LINDSEY BLAKE · 2018 to 2022
$1.0M
Lipid mediators and their signaling in ocular surface inflammation and meibomian gland dysfunctionI01BX004893 · VA · MIAMI VA HEALTH CARE SYSTEM · PI GALOR, ANAT, MANDAL, NAWAJES · 2021 to 2025
–
A pilot study of the safety and feasibility of transcutaneous electrical nerve stimulation (TENS) for chronic ocular painI21RX003883 · VA · MIAMI VA HEALTH CARE SYSTEM · PI FELIX, ELIZABETH ROY · 2022 to 2023
abstractChronic ocular pain (COP) is a leading cause of eye care visits in the US and has a substantial impact on quality of life and visual functioning. Although many conditions underlie COP, such as dry eye disease or post-herpetic neuralgia, some people experience pain without significant ocular signs on examination or known risk factors (eg, traumatic injury). Antidepressant medications that act primarily on the central nervous system, such as tricyclic antidepressants and serotonin and norepinephrine reuptake inhibitors, are often used to treat patients with COP, but a recent Cochrane review and network meta-analysis investigating 25 different antidepressants concluded that only two serotonin and norepinephrine reuptake inhibitors, have sufficient data to support their use in chronic pain. For all other medications, the evidence was of low certainty. We contend that while these medications are not a cure-all for chronic pain or COP, it is premature to conclude that these medications have no role in their treatment. We provide a rationale for continued use of antidepressant medications as part of a multimodal targeted treatment for patients with COP.
Indexed as
Antidepressive AgentsChronic PainEye PainHumansQuality of LifeAntidepressive Agents
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Antidepressant Medication Use for Treatment of Chronic Ocular Pain. · full record | OpenQuestion